Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

MENLO PARK, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced that the manuscript detailing 24-month results from Stage 3 of the SAHARA randomized controlled trial (RCT) has been published ahead of print (PAP) by Optometry and Vision Science (Official Journal of the American Academy of Optometry) and is available online in pre-publication format.

Read more at globenewswire.com